drugset / Trial / NCT00137007

Zithromax EV in Community-Acquired Pneumonia (CAP)

NCT00137007

Phase 4 Completed 151 enrolled Pfizer
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The intravenous (IV) regimen containing azithromycin (Zithromax) plus ampicillin-sulbactam is consistent with current guidelines for the treatment of CAP. In fact the International guidelines for the treatment of CAP in hospitalised patients suggests the use of a combination between a b-lactam and a macrolide. This trial will allow investigators to evaluate the efficacy of azithromycin plus ampicillin-sulbactam in the treatment of hospitalized subjects with community acquired pneumonia. In addition, this trial will allow investigators to evaluate the safety and toleration of combination therapy.

Timeline

Start
2003-11
Primary completion
Completion
2005-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Ampicillin/sulbactam Small molecule Intravenous
Subject Azithromycin Small molecule Intravenous

Indications